stockportfolio.pro
Kiniksa Pharmaceuticals International, plc (KNSA)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
Kiniksa Pharmaceuticals International, plc revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $38.54M | $220.18M | $270.26M | $423.24M | $677.56M |
| Gross profit | — | — | — | — | $29.44M | $197.28M | $236.85M | $362.33M | $370.35M |
| Net income | $-64.87M | $-103.23M | $-161.87M | $-161.38M | $-157.92M | $183.36M | $14.08M | $-43.19M | $59.01M |
| Net margin | — | — | — | — | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% |
Source: Kiniksa Pharmaceuticals International, plc SEC filings (10-K).
What growth is priced into KNSA stock?
At today's market cap of $3.89B, Kiniksa Pharmaceuticals International, plc is priced for free-cash-flow growth of about 12.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $136.42M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 9 years of Kiniksa Pharmaceuticals International, plc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track KNSA in your portfolio →
Kiniksa Pharmaceuticals International, plc financial history by metric
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Kiniksa Pharmaceuticals International, plc — frequently asked questions
What is Kiniksa Pharmaceuticals International, plc's revenue?
Kiniksa Pharmaceuticals International, plc (KNSA) reported revenue of $677.56M for fiscal year 2025, up 60.1% from the prior year, according to its SEC filings.
Is Kiniksa Pharmaceuticals International, plc profitable?
Yes. KNSA earned net income of $59.01M in fiscal 2025, a net margin of 8.7%.
What is KNSA's P/E ratio?
Kiniksa Pharmaceuticals International, plc trades at a price-to-earnings ratio of about 55.5 based on the latest data in our nightly-refreshed cache.
How much debt does Kiniksa Pharmaceuticals International, plc have?
As of fiscal year 2025, KNSA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Kiniksa Pharmaceuticals International, plc's gross margin?
KNSA's gross margin was 54.7% in fiscal 2025 — gross profit of $370.35M on revenue of $677.56M.
What is Kiniksa Pharmaceuticals International, plc's market cap?
Kiniksa Pharmaceuticals International, plc (KNSA) has a market capitalization of about $3.89B, based on the latest data in our nightly-refreshed cache.
When does Kiniksa Pharmaceuticals International, plc's fiscal year end?
KNSA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into KNSA stock?
At today's market cap of $3.89B, Kiniksa Pharmaceuticals International, plc is priced for free-cash-flow growth of about 12.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $136.42M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from Kiniksa Pharmaceuticals International, plc's official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.